NCT04577703View on ClinicalTrials.gov

First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 8, 2014

Primary Completion Date

December 10, 2015

Study Completion Date

December 10, 2015

Conditions
Advanced Solid Tumors
Interventions
DRUG

CT053PTSA

CT053PTSA will be administered daily in fasting state

Trial Locations (1)

510060

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sunshine Lake Pharma Co., Ltd.

INDUSTRY

NCT04577703 - First-In-Human Phase I Trial of Ningetinib ( CT053PTSA ) in the Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter